#USA #Boulder #GLP-1 #Ambrosia Biosciences #GIP Receptor

Ambrosia Biosciences Unveils Novel Oral Molecule Programs

Ambrosia Biosciences Inc., a pioneering company in drug discovery, recently presented groundbreaking nonclinical data concerning two of its leading oral small molecule programs at ObesityWeek® 2026, held by The Obesity Society. The focus of their presentation was on a GLP-1 receptor agonist, designated AMB-895, and a GIP receptor antagonist, AMB-131.

The Promise of AMB-895

AMB-895, an innovative formulation intended for once-weekly administration, stood out in its ability to achieve sustained target coverage exceeding the EC70 threshold after a single 1 mg/kg oral dose in lean non-human primates. This consistency resulted in not only notable weight loss but also a reduction in food intake over a two-week period of administration. Specifically, participants experienced an impressive 8% mean weight reduction from their baseline figures by the fourteenth day.

Breakthroughs with AMB-131

On the other hand, AMB-131, the GIP receptor antagonist, exhibited superior exposure and target coverage across a 24-hour span in both mouse and non-human primate models. More strikingly, it augmented weight loss effects induced by semaglutide in a mouse model known for diet-induced obesity. These results signal a significant advancement in the treatment landscape of weight management and metabolic regulation.

Insights from Ambrosia’s CEO

Nick Traggis, the CEO of Ambrosia Biosciences, articulated the limitations of existing diabetes and obesity medications, emphasizing issues surrounding administration routes, tolerability, and scalability. He stated, "There exists an overwhelming opportunity to enhance patient experiences via novel long-acting oral small molecule therapies that afford dosing flexibility and potentially lower treatment costs." Moreover, he expressed confidence that future therapies for metabolic disorders will increasingly incorporate oral combination approaches, which can be tailored to maximize both efficacy and tolerability. Ambrosia’s current pipeline, which comprises AMB-895 for once-weekly use in conjunction with AMB-702 for daily use, as well as GIP receptor antagonists and amylin agonist programs, embodies this vision of comprehensively addressing metabolic health needs.

About Ambrosia Biosciences

Ambrosia Biosciences Inc. operates as a privately held enterprise dedicated to crafting next-generation oral small molecule treatments targeting obesity and various metabolic disorders. By synergizing structural drug design with in-house medicinal chemistry and biology, the firm is propelling a diverse pipeline of innovative therapies forward. Their ultimate aim is to broaden access to cardiometabolic treatment options that enhance patient experiences while minimizing both treatment costs and complexity. For more information about their initiatives and pipeline, one can visit their website.

Looking Ahead

As Ambrosia, armed with recent research findings, prepares for the next stages in drug development, the company remains acutely aware of inherent risks associated with drug creation. Their commitment to transparency is demonstrated through the forward-looking statements disclaimer included in communications, which alerts stakeholders to potential variances from anticipated outcomes due to evolving factors within the pharmaceutical landscape. In this dynamic and competitive realm, ensuring that both management and interested parties maintain realistic expectations is paramount. Ambrosia looks forward to navigating these challenges on its trajectory toward transformative contributions to public health in the field of metabolic disease management.